神经内分泌癌的基因导向治疗:对BRAF和MEK抑制剂的反应
Lovisa Falkman1, Anders Sundin2, Britt Skogseid1
1Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Upsala journal of medical sciences
|May 8, 2024
概括
BRAF V600E突变神经内分泌癌 (NEC) 显示对BRAF和MEK抑制剂的敏感性. 这支持使用DNA测序来确定NEC患者的治疗目标.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 转移性神经内分泌癌 (NEC) 的预后不好,除了白金化疗之外,标准治疗选择有限.
- 目前的指导方针建议考虑与BRAF V600E突变的NEC进行BRAF抑制剂组合,但证据很少.
- 有限的病例报告需要进一步调查针对BRAF突变NEC的向治疗的有效性.
研究的目的:
- 评估BRAF抑制剂组合治疗在BRAF V600E突变转移性神经内分泌癌患者中的有效性.
- 确认当前指导方针的临床有效性,建议针对这种特定的NEC亚型进行向治疗.
- 评估BRAF和MEK抑制剂治疗的BRAF突变NEC患者小队的反应和生存结果.
主要方法:
- 在乌普萨拉大学医院进行了一项单中心回顾性队列研究.
- 包括在2018年至2023年间被诊断出患有本病理学证实NEC的患者.
- 瘤组织进行了广泛的下一代测序 (NGS),以确定可向突变.
主要成果:
- 在分析的48名NEC患者中,有2名患有可向突变,两者在结肠-NEC中都含有BRAF V600E.
- 这两位患者都接受了二线治疗,分别是达布拉费尼布和特拉美丁尼布,显示瘤大小减少了31%和40%.
- 反应持续时间很短,总生存时间分别为12个月和9个月.
结论:
- BRAF V600E-突变的NEC对BRAF和MEK抑制剂的联合治疗表现出敏感性.
- 这些发现支持在NEC诊断中常规使用DNA测序,以确定可操作的目标.
- 向治疗可能为BRAF突变NEC.患者选择治疗途径.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
1.1K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Tumor Immunotherapy
518
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
518
